20 February 2019 (Wednesday) - Oncologist Newsletter

“The Oncologist” sent their most recent missive today. There was a section specifically addressing haematological stuff this time:

Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis

Steven M. Bair, Lauren E. Strelec, Tatyana A. Feldman et al.

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Michele Merli, Marco Frigeni, Laurent Alric et al.

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden

Winnie S. Liang, Jo‐Anne Vergilio, Bodour Salhia et al.

Interferon‐α Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study

Xiao‐Dong Mo, Yu Wang, Xiao‐Hui Zhang et al.